AvKare recalled 2,003 cartons of Chlorpromazine Hydrochloride Tablets on August 25, 2025. The recall stems from the presence of a foreign substance in the medication. Consumers should stop using the product immediately and seek guidance from healthcare providers.
Presence of a foreign substance.
Consumers and healthcare providers should stop using this product immediately. Contact AvKARE or your healthcare provider for guidance. Notification method: E-Mail
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled product is Chlorpromazine Hydrochloride Tablets, USP, 100 mg, packaged in 50-tablet cartons. Lot numbers include 47089 and 47604, with expiration dates of December 31, 2025, and March 31, 2026. The medication was distributed nationwide in the USA.
The recall is classified as Class II due to the potential health risks associated with the presence of a foreign substance in the tablets. This could pose a serious health risk to consumers.
There are no reported incidents or injuries associated with this recall at this time. Consumers are advised to discontinue use as a precaution.
Consumers should stop using the recalled Chlorpromazine Hydrochloride Tablets immediately. Contact AvKARE or consult a healthcare provider for further guidance on the recall.
For more information, consumers can email AvKARE or visit their website. The FDA recall notice can also be found at the provided link.
Get instant alerts for recalls that affect you. Free forever.
Glenmark Pharmaceuticals recalled nearly 97,000 packs of Ondansetron Orally Disintegrating Tablets on December 30, 2025. Defective blister packs may not fully seal, leading to tablets falling out. Consumers should stop using the product immediately and contact healthcare providers.
Novo Nordisk recalled Wegovy (semaglutide) injections on December 19, 2025, after discovering hair in prefilled syringes. The contamination poses a serious hazard to consumers. The recall affects all units distributed nationwide.
Novo Nordisk recalled Wegovy (semaglutide) Injection on December 19, 2025, due to hair found in a prefilled syringe. The recall affects products distributed nationwide in the United States. Consumers should stop using the product immediately and contact their healthcare provider.
Zydus Pharmaceuticals recalled over 2,100 bottles of TraZODONE Hydrochloride Tablets on December 19, 2025. Some tablets have surface dents that may affect medication integrity. Consumers should stop using the product immediately and seek guidance from healthcare providers.
CareFusion 213, LLC recalled 106,400 units of ChloraPrep Triple Swabsticks on December 17, 2025. The recall occurred due to a lack of assurance of sterility. Consumers must stop using the product immediately and contact CareFusion for guidance.
Merck Sharp & Dohme LLC recalled 845 kits of Noxafil Powdermix on December 12, 2025. The recall follows the discovery of potential metal particulates in the product. Consumers should stop using the medication immediately and contact their healthcare provider for further guidance.
Merck Sharp & Dohme LLC recalled 3 single-dose kits of Emend (aprepitant) on December 12, 2025. The recall stems from the potential presence of metal particulates in the medication. Consumers should immediately stop using the product and contact their healthcare provider for guidance.
Beaver-Visitec International recalled five units of the OME6000U Laser and Endoscopy System on December 5, 2025. The recall stems from a manufacturing deviation where ferrites required for the USB cable were not installed. This omission poses a high electrical hazard risk to patients and healthcare providers.